K. Anderle

发表

ISSUES ASSOCIATED WITH SAFETY TESTING OF BLOOD PRODUCTS IN ENDEMIC AREAS

J. Eibl, G. Eder, K. Anderle, 1988, British journal of haematology.

Low risk of viral infection after administration of vapor‐heated factor VII concentrate or factor IX complex in first‐time recipients of blood components. International Factor Safety Study Group

M. Hilgartner, L. Aledort, G. Rivard, 1995, Transfusion.

Low risk of viral infection after administration of vapor‐heated factor VIII concentrate

P. Mannucci, D. Brettler, M. Hilgartner, 1992, Transfusion.

Comparison of the recovery and half‐life of a high‐purity factor IX concentrate with those of a factor IX complex concentrate. Factor IX Study Group

M. Morfini, L. Aledort, M. Kunschak, 1995, Transfusion.

Rheology of Aqueous Solutions of Okra Mucilage F

K. Anderle, J. Meister, George Merriman, 1983 .

Review of studies with plasminogen concentrates and proposals for further therapeutic strategies with plasminogen concentrates.

K. Anderle, A. Fröhlich, 1988, Haemostasis.

REDUCED FIBRINOLYTIC POTENTIAL IN PATIENTS WITH ARTERIAL OCCLUSIVE DISEASE (AOD) IN COMPARISON WITH NORMAL SUBJECTS

G. Anger, D. Hartl, K. Anderle, 1987, Thrombosis and Haemostasis.

The Clinical Application of Feiba Immuno in Factor VIII Inhibitor Patients

K. Anderle, 1977, Thrombosis and Haemostasis.